News
Company News: Motion Capture Group Retains Biotech Alliances International to Raise Series A $15 Million Financing Round
– Proceeds to be used for the clinical validation of pioneering real-world motion analysis solutions and MotionMarkers for chronic movement disorders
Motion Capture Group (MCG), a motion analysis and digital care company, today announced that it has exclusively contracted the investment bank Biotech Alliances International Inc. for its planned $15 million Series A capital raise. Read more…
Company News: BellaSeno Presents Case Study on Regulatory Approval of Novel 3D-Printed Medical Devices
— Presentation by BellaSeno’s CTO Mohit P. Chhaya at 3DMedLive Conference in London
— Identifying an approval pathway for novel scaffolds in absence of regulatory standards
BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced that its CTO Dr. Mohit Chhaya presented BellaSeno’s approach to obtain regulatory approval for its pioneering 3D-printed scaffold as a medical device in an uncertain regulatory environment. The presentation was held during the 3DMedLive Conference in London on October 3, 2019. Read more…
Company News: Novel Data on BellaSeno’s Biodegradable Breast Implants to Be Presented by Co-Founder DProf. Dietmar Hutmacher at Upcoming Plastic Surgery Conference
— Two presentations at the 50th Annual Conference of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRÄC)
— Recent publication in scientific journal Additive Manufacturing
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technologies, today announced that its co-founder Dietmar W. Hutmacher will introduce BellaSeno’s novel approach for breast reconstruction using 3-D-printed scaffolds during the 50th Annual Conference of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRÄC) in Hamburg, Germany.
Company News: Curetis Reports Financial Results for the First Six Months of 2019
– Strategic transaction to combine businesses with OpGen Inc.
– Revenues increased by approximately 35% year-on-year
– Progressing regulatory product approvals in the U.S. and China
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2019, and provided a business update for 2019 year-to-date and its outlook for the future. Read more…